Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2025)

Arcus Biosciences has reported Free Cash Flow over the past 9 years, most recently at -$121.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$121.0 million for Q4 2025, down 19.8% from a year ago — trailing twelve months through Dec 2025 was -$484.0 million (down 175.0% YoY), and the annual figure for FY2025 was -$484.0 million, down 175.0%.
  • Free Cash Flow for Q4 2025 was -$121.0 million at Arcus Biosciences, down from -$97.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for RCUS hit a ceiling of $651.0 million in Q1 2022 and a floor of -$133.0 million in Q1 2025.
  • Median Free Cash Flow over the past 5 years was -$77.4 million (2021), compared with a mean of -$42.0 million.
  • Biggest five-year swings in Free Cash Flow: soared 1030.57% in 2022 and later tumbled 4333.33% in 2025.
  • Arcus Biosciences' Free Cash Flow stood at -$83.3 million in 2021, then increased by 9.99% to -$75.0 million in 2022, then plummeted by 41.33% to -$106.0 million in 2023, then grew by 4.72% to -$101.0 million in 2024, then fell by 19.8% to -$121.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$121.0 million (Q4 2025), -$97.0 million (Q3 2025), and -$133.0 million (Q2 2025) per Business Quant data.